649 related articles for article (PubMed ID: 34071309)
1. Association between
Agwa SHA; Kamel MM; Elghazaly H; Abd Elsamee AM; Hafez H; Girgis SA; Ezz Elarab H; Ebeid FSE; Sayed SM; Sherif L; Matboli M
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34071309
[TBL] [Abstract][Full Text] [Related]
2. The association between interferon lambda 3 and 4 gene single-nucleotide polymorphisms and the recovery of COVID-19 patients.
Rahimi P; Tarharoudi R; Rahimpour A; Mosayebi Amroabadi J; Ahmadi I; Anvari E; Siadat SD; Aghasadeghi M; Fateh A
Virol J; 2021 Nov; 18(1):221. PubMed ID: 34775984
[TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Association Study Identifies TLL1 Variant Associated With Development of Hepatocellular Carcinoma After Eradication of Hepatitis C Virus Infection.
Matsuura K; Sawai H; Ikeo K; Ogawa S; Iio E; Isogawa M; Shimada N; Komori A; Toyoda H; Kumada T; Namisaki T; Yoshiji H; Sakamoto N; Nakagawa M; Asahina Y; Kurosaki M; Izumi N; Enomoto N; Kusakabe A; Kajiwara E; Itoh Y; Ide T; Tamori A; Matsubara M; Kawada N; Shirabe K; Tomita E; Honda M; Kaneko S; Nishina S; Suetsugu A; Hiasa Y; Watanabe H; Genda T; Sakaida I; Nishiguchi S; Takaguchi K; Tanaka E; Sugihara J; Shimada M; Kondo Y; Kawai Y; Kojima K; Nagasaki M; Tokunaga K; Tanaka Y;
Gastroenterology; 2017 May; 152(6):1383-1394. PubMed ID: 28163062
[TBL] [Abstract][Full Text] [Related]
4. TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy.
Iio E; Matsuura K; Shimada N; Atsukawa M; Itokawa N; Abe H; Kato K; Takaguchi K; Senoh T; Eguchi Y; Nomura H; Yoshizawa K; Kang JH; Matsui T; Hirashima N; Kusakabe A; Miyaki T; Fujiwara K; Matsunami K; Tsutsumi S; Iwakiri K; Tanaka Y
J Gastroenterol; 2019 Apr; 54(4):339-346. PubMed ID: 30382363
[TBL] [Abstract][Full Text] [Related]
5. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients.
Enomoto H; Aizawa N; Hasegawa K; Ikeda N; Sakai Y; Yoh K; Takata R; Yuri Y; Kishino K; Shimono Y; Ishii N; Takashima T; Nishimura T; Nishikawa H; Iwata Y; Iijima H; Nishiguchi S
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349377
[TBL] [Abstract][Full Text] [Related]
6. Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients.
Wulandari L; Hamidah B; Pakpahan C; Damayanti NS; Kurniati ND; Adiatmaja CO; Wigianita MR; Soedarsono ; Husada D; Tinduh D; Prakoeswa CRS; Endaryanto A; Puspaningsih NNT; Mori Y; Lusida MI; Shimizu K; Oceandy D
Hum Genomics; 2021 May; 15(1):29. PubMed ID: 34001248
[TBL] [Abstract][Full Text] [Related]
7. Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans.
Fu S; Karim D; Prieto J; Balderramo D; Ferrer JD; Mattos AZ; Arrese M; Carrera E; Oliveira J; Debes JD; Boonstra A
Ann Hepatol; 2024; 29(2):101181. PubMed ID: 37981236
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in the TLL1 gene is not associated with fibrosis in patients with metabolic associated fatty liver disease.
Bayoumi A; Jalil I; Metwally M; Adams LA; Aller R; García-Monzón C; Arias-Loste MT; Miele L; Petta S; Craxì A; Gallego-Durán R; Fischer J; Berg T; Qiao L; Liddle C; Bugianesi E; Romero-Gomez M; George J; Eslam M
PLoS One; 2020; 15(12):e0243590. PubMed ID: 33306709
[TBL] [Abstract][Full Text] [Related]
9. Combination of PNPLA3 and TLL1 polymorphism can predict advanced fibrosis in Japanese patients with nonalcoholic fatty liver disease.
Seko Y; Yamaguchi K; Mizuno N; Okuda K; Takemura M; Taketani H; Hara T; Umemura A; Nishikawa T; Moriguchi M; Yasui K; Kamaguchi M; Nishioji K; Mochizuki N; Kobayashi M; Mori K; Tanaka S; Matsuura K; Tanaka Y; Itoh Y
J Gastroenterol; 2018 Mar; 53(3):438-448. PubMed ID: 28744823
[TBL] [Abstract][Full Text] [Related]
10. Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.
Galani IE; Rovina N; Lampropoulou V; Triantafyllia V; Manioudaki M; Pavlos E; Koukaki E; Fragkou PC; Panou V; Rapti V; Koltsida O; Mentis A; Koulouris N; Tsiodras S; Koutsoukou A; Andreakos E
Nat Immunol; 2021 Jan; 22(1):32-40. PubMed ID: 33277638
[TBL] [Abstract][Full Text] [Related]
11. Association of TMPRSS2 Gene Polymorphisms with COVID-19 Severity and Mortality: a Case-Control Study with Computational Analyses.
Rokni M; Heidari Nia M; Sarhadi M; Mirinejad S; Sargazi S; Moudi M; Saravani R; Rahdar S; Kargar M
Appl Biochem Biotechnol; 2022 Aug; 194(8):3507-3526. PubMed ID: 35386063
[TBL] [Abstract][Full Text] [Related]
12. Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients.
Verma S; Abbas M; Verma S; Khan FH; Raza ST; Siddiqi Z; Ahmad I; Mahdi F
Infect Genet Evol; 2021 Jul; 91():104801. PubMed ID: 33676010
[TBL] [Abstract][Full Text] [Related]
13. The Interleukin-6 gene variants may protect against SARS-CoV-2 infection and the severity of COVID-19: a case-control study in a Moroccan population.
Noureddine R; Baba H; Aqillouch S; Abounouh K; Laazaazia O; Elmessaoudi-Idrissi M; Bahmani FZ; Tanouti IA; Ouladlahsen A; Sarih M; Dehbi H; Ezzikouri S
BMC Med Genomics; 2024 May; 17(1):139. PubMed ID: 38783290
[TBL] [Abstract][Full Text] [Related]
14. Relationship of Toll-Like Receptor 7, 9, and 10 Polymorphisms and the Severity of Coronavirus Disease 2019.
Bayyurt B; Baltacı S; Şahin NÖ; Arslan S; Bakır M
Jpn J Infect Dis; 2024 May; 77(3):161-168. PubMed ID: 38296538
[TBL] [Abstract][Full Text] [Related]
15. Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification.
Grolmusz VK; Bozsik A; Papp J; Patócs A
Front Immunol; 2021; 12():653489. PubMed ID: 33763088
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of toll-like receptors gene polymorphism on outcome of COVID-19 pneumonia: A case-control study.
Alseoudy MM; Elgamal M; Abdelghany DA; Borg AM; El-Mesery A; Elzeiny D; Hammad MO
Clin Immunol; 2022 Feb; 235():108929. PubMed ID: 35063671
[TBL] [Abstract][Full Text] [Related]
17. COVID-19: Risk Factors Associated with Infectivity and Severity.
Fadl N; Ali E; Salem TZ
Scand J Immunol; 2021 Jun; 93(6):e13039. PubMed ID: 33710663
[TBL] [Abstract][Full Text] [Related]
18. IFNL4 genetic variant can predispose to COVID-19.
Saponi-Cortes JMR; Rivas MD; Calle-Alonso F; Sanchez JF; Costo A; Martin C; Zamorano J
Sci Rep; 2021 Oct; 11(1):21185. PubMed ID: 34707167
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 multifaceted interaction with the human host. Part II: Innate immunity response, immunopathology, and epigenetics.
Beacon TH; Su RC; Lakowski TM; Delcuve GP; Davie JR
IUBMB Life; 2020 Nov; 72(11):2331-2354. PubMed ID: 32936531
[TBL] [Abstract][Full Text] [Related]
20. Kinetic Multi-omic Analysis of Responses to SARS-CoV-2 Infection in a Model of Severe COVID-19.
Cantwell AM; Singh H; Platt M; Yu Y; Lin YH; Ikeno Y; Hubbard G; Xiang Y; Gonzalez-Juarbe N; Dube PH
J Virol; 2021 Sep; 95(20):e0101021. PubMed ID: 34319784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
